CYP3A5 genotype does not influence everolimus in vitro metabolism and clinical pharmacokinetics in renal transplant recipients

Transplantation

Volumn 91, Issue 6, 2011, Pages 652-656

  Picard, Nicolas ^a,b,c   Rouguieg Malki, Koukeb ^a,b   Kamar, Nassim ^d   Rostaing, Lionel ^b,d   Marquet, Pierre ^a,b,c  

^a Univ Limoges   (France)

^b UNIVERSITY OF LIMOGES   (France)

^c LIMOGES UNIVERSITY HOSPITAL   (France)

^d CHU RANGUEIL   (France)

Author keywords

Drug metabolism; Everolimus; Pharmacogenetics; Pharmacokinetics

Indexed keywords

ADENINE; BASILIXIMAB; CORTICOSTEROID; CYTOCHROME P450 2C8; CYTOCHROME P450 3A4; CYTOCHROME P450 3A5; EVEROLIMUS; GUANINE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; RECOMBINANT ENZYME; TACROLIMUS; THYMOCYTE ANTIBODY;

ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG HALF LIFE; DRUG METABOLISM; ENZYME ACTIVE SITE; FEMALE; GENE FREQUENCY; GENETIC ASSOCIATION; GENOTYPE; GRAFT RECIPIENT; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; KIDNEY TRANSPLANTATION; LIVER METABOLISM; LIVER MICROSOME; MALE; MAXIMUM PLASMA CONCENTRATION; MORNING DOSAGE; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM; TIME TO MAXIMUM PLASMA CONCENTRATION;

ADULT; AGED; CYTOCHROME P-450 CYP3A; FEMALE; GENOTYPE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; SIROLIMUS;

EID: 79952775563     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/TP.0b013e31820ae4ac     Document Type: Article

References (19)

1. Formica RN Jr, Lorber KM, Friedman AL, et al. The evolving experience using everolimus in clinical transplantation. Transplant Proc 2004; 36(suppl 2): 495S.
2. Jacobsen W, Serkova N, Hausen B, et al. Comparison of the in vitro metabolism of the macrolide immunosuppressants sirolimus and RAD. Transplant Proc 2001; 33: 514.
3. Thervet E, Loriot MA, Barbier S, et al. Optimization of initial tacrolimus dose using pharmacogenetic testing. Clin Pharmacol Ther 2010; 87: 721.
4. MacPhee IA, Holt DW. A pharmacogenetic strategy for immunosuppression based on the CYP3A5 genotype. Transplantation 2008; 85: 163.
5. Anglicheau D, Le Corre D, Lechaton S, et al. Consequences of genetic polymorphisms for sirolimus requirements after renal transplant in patients on primary sirolimus therapy. Am J Transplant 2005; 5: 595.
6. Le Meur Y, Djebli N, Szelag JC, et al. CYP3A5*3 influences sirolimus oral clearance in de novo and stable renal transplant recipients. Clin Pharmacol Ther 2006; 80: 51.
7. Mourad M, Mourad G, Wallemacq P, et al. Sirolimus and tacrolimus trough concentrations and dose requirements after kidney transplantation in relation to CYP3A5 and MDR1 polymorphisms and steroids. Transplantation 2005; 80: 977.
8. Kniepeiss D, Renner W, Trummer O, et al. The role of CYP3A5 genotypes in dose requirements of tacrolimus and everolimus after heart transplantation. Clin Transplant 2009; [Epub ahead of print].
9. Kuehl P, Zhang J, Lin Y, et al. Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression. Nat Genet 2001; 27: 383.
10. Haufroid V, Wallemacq P, VanKerckhove V, et al. CYP3A5 and ABCB1 polymorphisms and tacrolimus pharmacokinetics in renal transplant candidates: Guidelines from an experimental study. Am J Transplant 2006; 6: 2706.
11. Macphee IA, Fredericks S, Mohamed M, et al. Tacrolimus pharmacogenetics: The CYP3A5*1 allele predicts low dose-normalized tacrolimus blood concentrations in whites and South Asians. Transplantation 2005; 79: 499.
12. Tsuchiya N, Satoh S, Tada H, et al. Influence of CYP3A5 and MDR1 (ABCB1) polymorphisms on the pharmacokinetics of tacrolimus in renal transplant recipients. Transplantation 2004; 78: 1182.
13. Picard N, Djebli N, Sauvage FL, et al. Metabolism of sirolimus in the presence or absence of cyclosporine by genotyped human liver microsomes and recombinant cytochromes P450 3A4 and 3A5. Drug Metab Dispos 2007; 35: 350.
14. Daly AK. Pharmacogenetics and human genetic polymorphisms. Biochem J 2010; 429: 435.
15. Miura M, Kagaya H, Satoh S, et al. Influence of drug transporters and UGT polymorphisms on pharmacokinetics of phenolic glucuronide metabolite of mycophenolic acid in Japanese renal transplant recipients. Ther Drug Monit 2008; 30: 559.
16. Benkali K, Premaud A, Picard N, et al. Tacrolimus population pharmacokinetic-pharmacogenetic analysis and Bayesian estimation in renal transplant recipients. Clin Pharmacokinet 2009; 48: 805.
17. Picard N, Cresteil T, Premaud A, et al. Characterization of a phase 1 metabolite of mycophenolic acid produced by CYP3A4/5. Ther Drug Monit 2004; 26: 600.
18. Obach RS. Prediction of human clearance of twenty-nine drugs from hepatic microsomal intrinsic clearance data: An examination of in vitro half-life approach and nonspecific binding to microsomes. Drug Metab Dispos 1999; 27: 1350.
19. Venkatakrishnan K, von Moltke LL, Greenblatt DJ. Application of the relative activity factor approach in scaling from heterologously expressed cytochromes p450 to human liver microsomes: Studies on amitriptyline as a model substrate. J Pharmacol Exp Ther 2001; 297: 326.